Background: In RESEARCH study, we demonstrated the superiority of ezetimibe add-on therapy over statin-doubling in T2DM.Non-HDL-C is attracting attention as an index including TG rich lipoproteins reflecting insulin resistance in diabetics.

Methods: 109 T2DM adults with LDL-C >=120 mg/dL (>=100 mg/dL in secondary preventive) despite statin treatment were randomly assigned to statin doubling group (S) or adding ezetimibe (E) for 12 weeks.As a post-hoc analysis, non-HDL-C change and TG rich lipoproteins were analyzed.

Results: The rate of non-HDL-C reduction was significantly greater in E(20.9%) than in S(8.3%). Assuming the non-HDL-C target as <150 mg/dl (<130 mg/dl for secondary preventive), the achievement rate was significantly higher in E(88.7%) than in S(57.1%). The rates of apoB and apoE reduction were significantly larger in E (apoB 14.8% and apoE 7.7%) than in S (apoB 9.0% and apoE 2.9%). By regression analysis, apoE change rate showed correlation with sd-LDL change rate or RLP-C change rate, respectively, with larger correlation and regression coefficient in E. The percentage change in non-HDL-C was correlated with the percentage change in sd-LDL, with larger regression coefficient in E. Analysis was also made for 43 subjects with TG>=150 mg/dl before treatment, and 73 subjects without achievement in the non-HDL-C target before treatment. Non-HDL-C reduction rates were greater in E (21.1% and 25.1%) than in S (8.9% and 8.7%), respectively. Target achievement rates were also significantly larger in E (77.8% and 83.9%) than in S (48.0% and 42.9%). ApoB reduction was 13.2% and 11.6% in S, and 12.5% and 17.1% E, and apoE reduction was 9.4% and 5.4% in S and 13.0% and 9.4% in E, respectively. The correlation of change rates showed almost the same tendency compared to the whole population.

Conclusion: Ezetimibe combination therapy effectively reduced non-HDL-C reflecting TG rich lipoproteins, compared with statin-doubling therapy.


K. Sakamoto: None. M. Kawamura: None. M. Tagami: None. A. Tanaka: Research Support; Self; Daiichi Sankyo Company, Limited. Speaker's Bureau; Self; Merck Sharp & Dohme Corp., Kewpie Corporation. Y. Mori: None. T. Hirano: Speaker's Bureau; Self; Novo Nordisk Inc., AstraZeneca. T. Shiba: Speaker's Bureau; Self; Shionogi & Co., Ltd., Pfizer Inc., Merck Sharp & Dohme Corp., Kowa Company, Ltd., Daiichi Sankyo Company, Limited.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at